Entresto: Why Is There Silence? We're Not Selling iPhones

— The drug hailed as a true PARADIGM shift, is slow out of the gate

by Peggy Peck, Editor-in-Chief, MedPage Today April 4, 2016

This article is a collaboration between MedPage Today and:

CHICAGO -- More than 18 months after , reported that Entresto (sacubitril/valsarta) reduced mortality in heart failure, and 8 months after the FDA approved the drug, guidelines have not been changed and physicians have been slow to prescribe it. Why?

�鶹������ýӰ��

Entresto: Why Is There Silence? We're Not Selling iPhones

— The drug hailed as a true PARADIGM shift, is slow out of the gate

�鶹��ýӰ��